

The Future of Early Cancer Diagnosis

NEW clinical data & exclusive report available at VCS 2020

Volition Veterinary Diagnostics Development

are delighted to be leading the conversation about early cancer diagnosis at VCS Virtual Conf 2020 via:

- two abstract presentations
- launch of expert endorsed *"A look to the future of cancer diagnosis"* report

NEW clinical data being presented:

Defining the nucleosome compartment in the plasma of dogs with lymphoma

Friday 16th October, 1:30pm

Defining the nucleosome compartment in the plasma of dogs with hemangiosarcoma

Saturday 17th October, 11:15am



"At Volition Veterinary we're committed to streamlining the cancer diagnostic process with the aim to aid earlier detection of cancer and the saving of lives. We're excited to share our new data and give delegates exclusive first access to our expert report."

Heather Wilson-Robles, Associate Professor & Dr Fred A and Vola N Palmer Chair in Comparative Oncology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University and President-Elect of VCS

Chief Medical Officer, Volition Veterinary

Visit Volition Veterinary virtual stand at VCS

to find out more and to request a copy of our **free** report, *"A look to the future of cancer diagnosis"*

With contributions from leading veterinary oncologists, the report considers barriers to early canine cancer detection and the future of diagnostic techniques.

Introducing Volition Veterinary Diagnostics Development – pioneers of Nucleosomics™ testing



Volition is a multi-national epigenetics company developing simple, easy to use, cost effective **blood tests** to help diagnose a range of cancers and other diseases in both humans and **animals**.

The tests are based on the science of Nucleosomics™; the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - a novel and targeted way to identify certain diseases. Volition Veterinary is the only company known to be working on ELISA measurement for epigenetically modified circulating nucleosomes.

Introducing Nu.Q™ Vet

Cancer is the **most common** cause of death in dogs over the age of two years old in the U.S. with more than 50% of all dogs over the age of ten developing cancer in their lifetimes.

Early detection of cancer can not only help saves lives, it can also improve the quality of life of the dog and its owner. The Nu.Q Vet Diagnostics Platform is a simple, low-cost, easy to use ELISA based blood test which will help streamline the diagnostic process for malignancies in dogs.

The benefit for the both vet, owner and dog is a streamlined diagnostic process with the aim to aid earlier detection of cancer and the saving of lives.

Nu.Q™ Vet Cancer Screening Test data being presented at VCS is for both **Lymphoma and Hemangiosarcoma detection**.

.....

For more information about Nu.Q Vet™ and the future of early cancer diagnosis join our abstract presentations, visit our virtual exhibition stand or email NuQVet@volition.com

.....